BRAINAURORA-B Reports 2025 Annual Results: Shareholder Loss Widens to 315 Million Yuan

Stock News03-31

BRAINAURORA-B (06681) announced its annual results for the period ended December 31, 2025. Revenue reached 220 million yuan, representing a year-on-year increase of 79.91%. The loss attributable to the company's owners was 315 million yuan, widening by 58.8% compared to the previous year. The basic loss per share was 0.27 yuan.

The increase in revenue during the period was primarily attributable to several factors. Firstly, by the end of 2025, the number of hospitals that had formally established cooperative relationships increased to 206. These partner hospitals are widely distributed, with a primary focus on the Pearl River Delta, Beijing-Tianjin-Hebei region, as well as Sichuan and Henan provinces, and are gradually expanding to cover core cities in central and northern China. This expansion has laid a solid channel foundation for the large-scale application of the company's products nationwide.

Secondly, significant improvements were achieved in key operational metrics for home-based users. The number of times patients used the company's system increased from approximately 1.8 million times in 2024 to about 3.3 million times by the end of 2025. The average monthly active users grew from 2,154.67 in 2024 to 4,290.75 in 2025, an increase of 99.14%. In December 2025, the number of monthly active users reached 10,229, a 72.52% increase compared to 5,929 users in the same month of 2024. Furthermore, the average daily usage time per user in 2025 was 23.29 minutes, demonstrating strong user engagement and adherence to interventions.

Thirdly, the company generated additional revenue of 49.78 million yuan from the sales of its medical AI large language model solutions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment